NovaBay Pharmaceuticals

Equities

NBY

US66987P3001

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0788 ^USD	+2.34%		-4.37%	-61.37%

Mar. 26	Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Mar. 26	NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

July 06, 2023 at 05:01 pm EDT

On June 29, 2023, Dr. Audrey Kunin advised NovaBay Pharmaceuticals, Inc. of her decision to retire and resign from her position as the Companyâ€™s Chief Product Officer effective as of November 5, 2023, the natural expiration of her Executive Employment Agreement, dated November 5, 2021.

Latest news about NovaBay Pharmaceuticals

Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M	Mar. 26	MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc..	Mar. 24	CI
NovaBay Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2023	Mar. 14	CI
New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. for $1.07 million.	Mar. 13	CI
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	Mar. 13	CI
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma?s Extensive Distributor Network	Jan. 09	CI
Transcript : NovaBay Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q3 Revenue $3.3M, vs. Street Est of $3.55M	Nov. 09	MT
Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft	23-09-14	CI
NovaBay to Commercialize BioStem's Amniotic Tissue Allograft	23-09-11	MT
NovaBay Pharmaceuticals, Inc. Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova®? Allograft	23-09-11	CI
Ladenburg Thalmann Cuts Price Target on NovaBay Pharmaceuticals to $3.80 From $6, Maintains Buy Rating	23-08-11	MT
Transcript : NovaBay Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q2 Revenue $4.6M, vs. Street Est of $3.7M	23-08-10	MT
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023	23-07-06	CI
Novabay Pharmaceuticals, Inc. Approves to Elect Mijia Wu as Director	23-06-14	CI
NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price	23-06-12	CI
Wall Street Set to Open Higher; Investors Look to Powell Speech for Fed Action Hints	23-05-19	MT
US Futures Trend Higher Pre-Bell Ahead of Powell Speech	23-05-19	MT
Top Premarket Gainers	23-05-19	MT

Chart NovaBay Pharmaceuticals

Duration

Period

More charts

Company Profile

NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells consumer products for the eyecare and skincare markets. The Company's lead product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have antimicrobial properties as it removes foreign material, such as microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with its form of hypochlorous acid and is cleared by the United States Food and Drug Administration (FDA) for sale in the United States. Its other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress and the i-Chek. Avenova Spray is available both over-the-counter and as a prescription. Avenova Spray is also available at optometrists and ophthalmologists offices; at national pharmacy chains across all over 50 states, and through its Partner Pharmacy Program.

Sector

More about the company